Brokers Set Expectations for Genelux Co.’s Q1 2024 Earnings (NASDAQ:GNLX)
Genelux Co. (NASDAQ:GNLX – Free Report) – Equities researchers at Brookline Capital Management issued their Q1 2024 earnings per share estimates for shares of Genelux in a report released on Monday, April 1st. Brookline Capital Management analyst K. Dolliver forecasts that the company will earn ($0.15) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.15) EPS and Q4 2024 earnings at ($0.16) EPS.
Other equities research analysts have also issued research reports about the company. HC Wainwright cut their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. Benchmark reiterated a “speculative buy” rating and issued a $30.00 price target on shares of Genelux in a research note on Wednesday.
Get Our Latest Stock Report on GNLX
Genelux Trading Down 7.4 %
Shares of GNLX stock opened at $4.86 on Wednesday. Genelux has a 52-week low of $4.86 and a 52-week high of $40.98. The stock has a fifty day simple moving average of $7.50 and a two-hundred day simple moving average of $13.19.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Genelux by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 998,810 shares of the company’s stock valued at $13,993,000 after purchasing an additional 17,817 shares in the last quarter. Wellington Management Group LLP purchased a new position in Genelux in the fourth quarter worth about $361,000. Clarity Capital Partners LLC purchased a new position in Genelux in the fourth quarter worth about $364,000. Barclays PLC grew its position in Genelux by 652.5% in the fourth quarter. Barclays PLC now owns 25,465 shares of the company’s stock worth $357,000 after acquiring an additional 22,081 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in Genelux by 16.4% in the fourth quarter. Nuveen Asset Management LLC now owns 57,790 shares of the company’s stock worth $810,000 after acquiring an additional 8,162 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles
Receive News & Ratings for Genelux Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genelux and related companies with MarketBeat.com’s FREE daily email newsletter.
